

Docket No.: 018813-0272487

IN THE UNITED STAFES PATENT AND TRADEMARK OFFICE

In re the Application of:

Group Art Unit: 1652

GEORGE P. VLASUK, et al.

Examiner: Moore, W.

Serial No.: 09/498,556

Filed: February 4, 2000

Title: NEMATODE-EXTRACTED SERINE

PROTEASE INHIBITORS AND ANTICOAGULANT PROTEIN

RESPONSE TO NOTICE TO COMPLY

United States Patent and Trademark Office 2011 South Clark Place Attn: Box Sequence Crystal Plaza Two Lobby, Room 1B02 Arlington, VA 22202

Sir:

Responsive to the communication mailed June 17, 2002, Applicants submit herewith a paper copy and a computer readable form (CRF) of the sequence listing as required under 37 C.F.R. §1.824 (a). The sequence listing is provided in Plain Text format on the accompanying diskette. A copy of the Notice to Comply is attached to this response.

The paper copy and CFR of the sequence listing are identical and do not add new matter. A statement under 37 C.F.R. §1.821 (f) and (g) to that effect is provided. Accordingly, please amend the specification by entering the enclosed sequence listing.

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. §1.10

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being mailed via "Express Mail Post Office to Addressee" service of the United States Postal Services on the date shown below in an envelope addressed to the United States Patent and Trademark Office, 2011 South Clark Place,

Attn: Box Sequence, Crystal Plaza Two, Lobby, Room 1B02, Arlington, VA 22202.

Dated # 17 / 52

SUZANNEL. SIMPSON

Express Mail Label No. F 1/08 42 35 538 45

If the fee authorized is incorrect or if any other fees are due in connection with this submission, please charge any such fee or credit any overpayment to Deposit Account No. 03-3975.

Respectfully submitted,

Pillsbury Winthrop LLP

y:_____

Suzanne L. Biggs Reg. No.: 30,158

Tel. No.: (858) 509-4095 Fax No.: (858) 509-4010

CUSTOMER ID. NO. 27500

PILLSBURY WINTHROP LLP 11682 El Camino Real, Suite 200 San Diego, CA 92130

CER	<u>TIFICATE OF</u>	EXPRESS [<u> 11</u>	<u> AILING</u>	<u>_</u>	<u>JNDER</u>	3	<u>7 C.I</u>	<u> </u>	$\{1.10$	<u>, </u>

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being mailed via "Express Mail Post Office to Addressee" service of the United States Postal Services on the date shown below in an envelope addressed to the United States Patent and Trademark Office, 2011 South Clark Place,

Attn: Box Sequence, Crystal Plaza Two, Lobby, Room 1B02, Arlington, VA 22202.

Dated: _____ By: ______ Express Mail Label No. ______ SUZANNE L. SIMPSON

Notice to Comply

Application No. 09498556	vlasuk et al.	TECH CE		
Examiner MITRA	Art Unit 1653	NTER	60	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

1600/2900

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1 1.020 for the following reason(s).
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
⊡	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
Ra	7. Other: the amendment of10 Jan 2001 in claim 271 item (e) recites SEQ ID NO: 357. Note that the w Sequence listing Report indicates only 356 sequences. Correction is required. Note below re: new tter.
Αn	plicant Must Provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
into	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
app	A statement that the content of the paper and computer readable copies are the same and, where

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

1.825(d).

Technical Assistance......703-287-0200

To Purchase Patentln Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

